Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Objective: Fatty liver is associated with insulin resistance-related diseases, such as dyslipidemia, obesity, and type 2 diabetes. The aim of this study was to evaluate the association of dyslipidemia with fatty liver and assess the differences in these associations according to the degree of hepatic steatosis. Methods: A total of 2,462 subjects (1,679 men and 783 women) who underwent a comprehensive health check-up (including abdominal computed tomography) from January 2010 to December 2013 were enrolled at Samsung Changwon Hospital Healthcare Center. The liver attenuation index (LAI), defined as the difference between mean hepatic and splenic attenuation, was used to assess the degree of hepatic steatosis. An LAI below 5 Hounsfield units was defined as fatty liver. Results: We found that 32.2% of the study subjects had fatty liver. Serum low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG), and fasting blood glucose concentrations and glycated hemoglobin (HbA1c percentage) were significant greater in the fatty liver group compared with the non-fatty liver group, while serum high-density lipoprotein cholesterol (HDL-C) was significantly lower in the fatty liver group. Subjects with fatty liver had 1.7-fold greater risk of dyslipidemia than those without fatty liver after adjusting for age, sex, body mass index (BMI), and HbA1c. When individuals with fatty liver were analyzed by tertiles of LAI values, LDL-C, TG, fasting glucose, BMI, and HbA1c concentrations increased while HDL-C decreased with decreasing LAI tertiles. Compared with LAI tertile 3, the risk for dyslipidemia significantly increased with adjusted odds ratios of 1.42, and 1.81 in tertiles 2 and 1, respectively. Conclusion: Fatty liver was significantly associated with dyslipidemia and this association varied according to the degree of hepatic steatosis.
Abstract
Objective: Fatty liver is associated with insulin resistance-related diseases, such as dyslipidemia, obesity, and type 2 diabetes. The aim of this study was to evaluate the association of dyslipidemia with fatty liver and assess the differences in these associations according to the degree of hepatic steatosis. Methods: A total of 2,462 subjects (1,679 men and 783 women) who underwent a comprehensive health check-up (including abdominal computed tomography) from January 2010 to December 2013 were enrolled at Samsung Changwon Hospital Healthcare Center. The liver attenuation index (LAI), defined as the difference between mean hepatic and splenic attenuation, was used to assess the degree of hepatic steatosis. An LAI below 5 Hounsfield units was defined as fatty liver. Results: We found that 32.2% of the study subjects had fatty liver. Serum low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG), and fasting blood glucose concentrations and glycated hemoglobin (HbA1c percentage) were significant greater in the fatty liver group compared with the non-fatty liver group, while serum high-density lipoprotein cholesterol (HDL-C) was significantly lower in the fatty liver group. Subjects with fatty liver had 1.7-fold greater risk of dyslipidemia than those without fatty liver after adjusting for age, sex, body mass index (BMI), and HbA1c. When individuals with fatty liver were analyzed by tertiles of LAI values, LDL-C, TG, fasting glucose, BMI, and HbA1c concentrations increased while HDL-C decreased with decreasing LAI tertiles. Compared with LAI tertile 3, the risk for dyslipidemia significantly increased with adjusted odds ratios of 1.42, and 1.81 in tertiles 2 and 1, respectively. Conclusion: Fatty liver was significantly associated with dyslipidemia and this association varied according to the degree of hepatic steatosis.
참고문헌 (22)
- Mashek DG, "Hepatic lipid droplet biology: getting to the root of fatty liver", Hepatology, 62, pp.964~967 (2015)
- Katsiki N, "Non-alcoholic fatty liver disease and dyslipidemia: an update", Metabolism, 65, pp.1109~1123 (2016)
- Bae JC, "Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects", Am J Gastroenterol, 105, pp.2389~2395 (2010)
- Limanond P, "Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings", Radiology, 230, pp.276~280 (2004)
- Kodama Y, "Comparison of CT methods for determining the fat content of the liver", AJR Am J Roentgenol, 188, pp.1307~1312 (2007)
- 이은정, "2018 Guidelines for the management of dyslipidemia", The Korean Journal of Internal Medicine, 34(4), pp.723~771 (2019), 대한내과학회[DOI]
- Neuschwander-Tetri BA, "Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease", Hepatology, 52, pp.913~924 (2010)
- Ruhl CE, "Epidemiology of nonalcoholic fatty liver", Clin Liver Dis, 8, pp.501~519 (2004)
- Targher G, "Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease", N Engl J Med, 363, pp.1341~1350 (2010)
- Chatrath H, "Dyslipidemia in patients with nonalcoholic fatty liver disease", Semin Liver Dis, 32, pp.22~29 (2012)
- Lee SS, "Radiologic evaluation of nonalcoholic fatty liver disease", World J Gastroenterol, 20, pp.7392~7402 (2014)
- Younossi Z, "Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 69, pp.2672~2682 (2019)
- Bjornstad P, "Pathogenesis of lipid disorders in insulin resistance: a brief review", Curr Diab Rep, 18, pp.127~ (2018)
- Taskinen MR, "Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects", Arterioscler Thromb Vasc Biol, 31, pp.2144~2150 (2011)
- Bril F, "Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD", J Clin Endocrinol Metab, 101, pp.644~652 (2016)
- Sugino I, "Influence of fatty liver on plasma small, dense LDL-cholesterol in subjects with and without metabolic syndrome", J Atheroscler Thromb, 18, pp.1~7 (2011)
- Fedchuk L, "Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease", Aliment Pharmacol Ther, 40, pp.1209~1222 (2014)
- European Association for the Study of the Liver (EASL), "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
- Bae JC, "Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): a randomized controlled trial", Diabetes Care, 38, pp.1245~1252 (2015)
- Brunt EM, "Nonalcoholic fatty liver disease", Nat Rev Dis Primers, 1, pp.15080~ (2015)
- Klop B, "Alcohol and plasma triglycerides", Curr Opin Lipidol, 24, pp.321~326 (2013)
- Lieber CS, "Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis", Alcohol, 34, pp.9~19 (2004)